Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. [electronic resource]
Producer: 20140127Description: 779-87 p. digitalISSN:- 1573-7217
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- drug therapy
- Capecitabine
- Deoxycytidine -- administration & dosage
- Diarrhea -- chemically induced
- Disease-Free Survival
- Epirubicin -- administration & dosage
- Female
- Fluorouracil -- administration & dosage
- Hand-Foot Syndrome -- etiology
- Humans
- Middle Aged
- Paclitaxel -- administration & dosage
- Quality of Life
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.